Your browser is no longer supported. Please, upgrade your browser.
Settings
MESO Mesoblast Limited daily Stock Chart
MESO [NASD]
Mesoblast Limited
Index- P/E- EPS (ttm)-0.50 Insider Own- Shs Outstand98.43M Perf Week3.46%
Market Cap470.50M Forward P/E- EPS next Y-0.87 Insider Trans- Shs Float73.62M Perf Month19.50%
Income-47.80M PEG- EPS next Q-0.24 Inst Own3.00% Short Float0.10% Perf Quarter-35.23%
Sales27.80M P/S16.92 EPS this Y60.60% Inst Trans0.34% Short Ratio1.22 Perf Half Y-26.57%
Book/sh5.51 P/B0.87 EPS next Y8.40% ROA-7.00% Target Price14.55 Perf Year-19.66%
Cash/sh0.56 P/C8.55 EPS next 5Y24.00% ROE-8.70% 52W Range3.35 - 8.78 Perf YTD16.02%
Dividend- P/FCF- EPS past 5Y18.30% ROI-5.60% 52W High-45.56% Beta1.81
Dividend %- Quick Ratio3.60 Sales past 5Y-9.60% Gross Margin67.80% 52W Low42.69% ATR0.25
Employees81 Current Ratio3.60 Sales Q/Q866.70% Oper. Margin- RSI (14)57.75 Volatility3.70% 5.56%
OptionableYes Debt/Eq0.12 EPS Q/Q-154.30% Profit Margin- Rel Volume0.33 Prev Close4.82
ShortableYes LT Debt/Eq0.12 EarningsFeb 14 AMC Payout- Avg Volume57.53K Price4.78
Recom1.80 SMA2011.61% SMA50-1.80% SMA200-18.48% Volume19,183 Change-0.83%
Mar-22-18Downgrade Credit Suisse Neutral → Underperform
Feb-28-18Reiterated Cantor Fitzgerald Buy $20 → $23
Aug-31-17Initiated Oppenheimer Outperform $16
Jun-08-17Initiated Cantor Fitzgerald Buy
Jan-14-19 10:46AM  Hercules Capital Provides US$15M From Existing Facility for Mesoblast to Accelerate Product Commercialization Programs GlobeNewswire
Jan-13-19 04:56PM  Does The Mesoblast Limited (ASX:MSB) Share Price Tend To Follow The Market? Simply Wall St.
Jan-07-19 07:44PM  Mesoblast Highlights 2019 Key Priorities for its Leading Cellular Medicines Pipeline at Biotech Showcase in San Francisco GlobeNewswire
06:00AM  Phase 3 Trial of Mesoblasts Cell Therapy in Chronic Heart Failure Completes Recruitment GlobeNewswire
Dec-28-18 06:00AM  Mesoblast Corporate Review GlobeNewswire +9.72%
Dec-24-18 06:30AM  Mesoblast to Present at 2019 Biotech Showcase in San Francisco GlobeNewswire
Dec-19-18 07:22AM  Mesoblast Makes Executive Appointment to Drive Product Commercialization GlobeNewswire
Dec-13-18 06:00AM  Meetings Held With FDA Support Mesoblasts Planned Regulatory Filing for Commercialization of Remestemcel-L in Acute GVHD GlobeNewswire
Nov-29-18 07:35AM  Recent Analysis Shows HudBay Minerals, Meridian Bioscience, ArQule, Mesoblast, Concho Resources, and Liberty Global Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Nov-26-18 06:00AM  Tasly and Mesoblast Initiate Development and Regulatory Activities for MPC-150-IM Heart Failure Cell Therapy in China GlobeNewswire
Nov-15-18 04:33PM  Mesoblast Reports First Quarter Ended September 30, 2018 Financial Results and Operational Highlights GlobeNewswire
06:00AM  Mesoblast Financial Results Webcast for Quarter Ended September 30, 2018 GlobeNewswire
Nov-11-18 07:59PM  Clinically Meaningful Outcome in NIH Trial of MPC-150-IM for Heart Failure LVAD Recipients Provides Pathway for Potential Regulatory Approval GlobeNewswire
Nov-09-18 06:00AM  Mesoblast to Host Analyst Call on Results of End-Stage Heart Failure Trial Being Presented at 2018 American Heart Association Scientific Sessions GlobeNewswire
Oct-24-18 06:05AM  Mesoblast Expands Partnership With JCR Pharmaceuticals for Treatment of Wound Healing in Epidermolysis Bullosa GlobeNewswire -5.13%
Oct-22-18 08:25AM  Investor Expectations to Drive Momentum within ChannelAdvisor, WideOpenWest, Arcos Dorados, Mesoblast, Ferrari N.V, and Weatherford International Discovering Underlying Factors of Influence GlobeNewswire
Oct-12-18 06:00AM  Mesoblast and Tasly Pharmaceutical Group Complete Transaction for Strategic Cardiovascular Partnership in China GlobeNewswire
Oct-09-18 12:00PM  Orchestra BioMed Adds Three Industry Leaders to Strategic Advisory Board GlobeNewswire
Oct-02-18 06:00AM  Trial Results of Mesoblast Cell Therapy in End-Stage Heart Failure Selected as Late-Breaking Presentation at 2018 American Heart Association Scientific Sessions GlobeNewswire -17.79%
Sep-28-18 10:06AM  3 Biotech Stocks With Rising Estimates in the Past Month Zacks +7.23%
Sep-20-18 06:30AM  Children Treated With Remestemcel-L Continue to Have Strong Survival Outcomes at Six Months in Mesoblasts Phase 3 Trial for Acute Graft Versus Host Disease GlobeNewswire
Sep-17-18 06:00AM  Tasly Pharmaceutical Group Receives All Necessary Approvals for Transaction With Mesoblast GlobeNewswire
Aug-30-18 04:50PM  Mesoblast Limited (ASX:MSB) Is Expected To Breakeven Simply Wall St.
Aug-29-18 06:56PM  Mesoblast Reports Fourth Quarter and Full-Year 2018 Financial Results and Operational Highlights GlobeNewswire
07:43AM  Mesoblast's Earnings Outlook Benzinga
Aug-28-18 09:04PM  Mesoblast Provides Update on Transaction With Tasly Pharmaceutical Group GlobeNewswire
Aug-21-18 07:30AM  Analysis: Positioning to Benefit within Alamos Gold, Nomad Foods, MyoKardia, Mesoblast, Core-Mark Holding, and Jounce Therapeutics Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Jul-17-18 06:32AM  Mesoblast Enters Into Strategic Cardiovascular Alliance for China With Tasly Pharmaceutical Group GlobeNewswire +12.50%
06:17AM  BRIEF-Tasly Pharmaceutical To Invest $20 Million In Australia's Mesoblast Limited Reuters
Jul-11-18 06:00AM  Leading Commercial and Transactional Healthcare Executive Shawn Cline Tomasello Joins Mesoblast Board GlobeNewswire
Jul-02-18 06:00AM  Mesoblast Enters Into US$50M Financing with Novaquest Capital for Commercial Readiness of Remestemcel-l in the Treatment of Acute Graft Versus Host Disease GlobeNewswire +10.00%
Jun-21-18 09:28AM  Mesoblast Soars on Stem-Cell Treatment Data TheStreet.com +9.39%
06:00AM  Key Day 100 Survival Outcomes of Phase 3 Trial for Acute Graft Versus Host Disease Presented at 2018 ISSCR Annual Meeting GlobeNewswire
Jun-19-18 06:00AM  U.S. Healthcare Leader Joseph R. Swedish Joins Mesoblast Board GlobeNewswire
Jun-06-18 07:30AM  Investor Expectations to Drive Momentum within Mesoblast, Access National, Urogen Pharma, TechTarget, Sina, and CoStar Group Discovering Underlying Factors of Influence GlobeNewswire
May-30-18 07:32PM  Financial Results and Operational Highlights for the Third Quarter Ended March 31, 2018 GlobeNewswire +6.67%
06:41PM  Mesoblast Appoints New Chief Financial Officer GlobeNewswire
May-29-18 03:21PM  Mesoblast Financial Results Webcast for Quarter Ended March 31, 2018 GlobeNewswire
06:00AM  Mesoblast Partners With Cartherics to Develop off-the-shelf Cell-based Immunotherapies for Solid Cancers GlobeNewswire
May-08-18 06:00AM  Mesoblast Phase 3 Trial Results for Acute Graft Versus Host Disease Presented at 2018 International Society for Cell and Gene Therapy Annual Meeting GlobeNewswire
May-01-18 06:00AM  Mesoblast Cell Therapies Featured at Vatican International Healthcare Conference GlobeNewswire
Apr-23-18 04:26PM  Who Just Ramped Up Their Shares In Mesoblast Limited (ASX:MSB)? Simply Wall St.
Apr-20-18 07:20AM  Wired News - Mesoblast Announced Updated Data from Phase-3 and Phase-2b Clinical Trials of MPC-150-IM in Patients with Chronic Heart Failure ACCESSWIRE
Apr-18-18 06:00AM  Mesoblast Clinical Program Update for MPC-150-IM in Patients With Chronic Heart Failure GlobeNewswire
Apr-11-18 08:15AM  Investor Expectations to Drive Momentum within Xcerra, Grupo Aeroportuario del Centro Norte S.A.B. de C.V, WAVE Life Sciences, Hoegh LNG Partners LP, Mesoblast, and Intuitive Surgical Discovering Underlying Factors of Influence GlobeNewswire
Mar-30-18 08:15PM  Market Sentiment Around Loss-Making Mesoblast Limited (ASX:MSB) Simply Wall St.
Mar-28-18 06:25PM  Mesoblast Phase 3 Cell Therapy Trial for Chronic Low Back Pain Completes Enrollment GlobeNewswire
Mar-22-18 12:18PM  Mesoblast's Delayed Launches, Teva Split Turn Credit Suisse Bearish Benzinga
Mar-16-18 08:30AM  New Research: Key Drivers of Growth for CNB Financial, Akebia Therapeutics, Mesoblast, 21Vianet Group, Old Line Bancshares, and BioSpecifics Technologies Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Mar-06-18 07:31PM  Mesoblast Enters Into US$75 Million Non-Dilutive Credit Facility GlobeNewswire -6.09%
Feb-27-18 04:47PM  Mesoblast Operational Highlights and Financial Results for the Half-Year Ended December 31, 2017 GlobeNewswire -5.75%
Feb-26-18 04:00PM  2018 First Half Year Financial Results Webcast for Mesoblast GlobeNewswire +17.93%
Feb-21-18 06:00PM  Mesoblast stem cell therapy meets goal of pediatric Graft vs Host study Reuters
06:00PM  Primary Endpoint Successfully Achieved in Mesoblasts Phase 3 Cell Therapy Trial for Acute Graft Versus Host Disease GlobeNewswire
Feb-19-18 09:08PM  Is Mesoblast Limiteds (ASX:MSB) CEO Pay Fair? Simply Wall St.
Feb-12-18 01:49AM  Breaking Down Mesoblast Limiteds (ASX:MSB) Ownership Structure Simply Wall St.
Feb-02-18 10:51PM  What Is The Future Prospect For Healthcare And Mesoblast Limited (ASX:MSB)? Simply Wall St.
Jan-17-18 07:02PM  Best Growth Stocks To Buy Simply Wall St.
Jan-11-18 06:00AM  Mesoblast to Present at 36th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-28-17 12:23PM  ETFs with exposure to Mesoblast Ltd. : December 28, 2017 Capital Cube
Dec-27-17 08:43AM  Mesoblast Ltd. :MESO-US: Earnings Analysis: Q1, 2018 By the Numbers : December 27, 2017 Capital Cube
Dec-21-17 06:00AM  Mesoblast Receives FDA Regenerative Medicine Advanced Therapy Designation for Its Cell Therapy in Heart Failure Patients With Left Ventricular Assist Devices GlobeNewswire
Dec-20-17 11:58PM  FDA to fast track Mesoblast's cell therapy for heart failure Reuters
06:00AM  Mesoblasts Phase 3 Trial in Children With Acute Graft Versus Host Disease Completes Enrollment GlobeNewswire
Dec-18-17 07:50AM  Wired News TiGenix Received an Exclusive Global Patent License to Cx601 from Mesoblast in the Local Treatment of Fistulae ACCESSWIRE +15.33%
07:00AM  Tiny stem cell companies close in on major heart disease goals Reuters
01:17AM  Tiny stem cell companies close in on major heart disease goals Reuters
Dec-14-17 07:34PM  Mesoblast grants TiGenix an exclusive global patent license to use adipose-derived mesenchymal stem cells in the local treatment of fistulae GlobeNewswire
Dec-13-17 08:28PM  What You Must Know About Mesoblast Limiteds (ASX:MSB) Financial Health Simply Wall St.
Dec-11-17 06:00AM  Mesoblast Named Global Technology Leader in Cell Therapy Industry Business Wire
Dec-07-17 05:33PM  Mesoblast Named Global Technology Leader in Cell Therapy Industry GlobeNewswire
Nov-16-17 09:01AM  Caterpillar, Avon Products, JA Solar Holdings, Mesoblast and 21Vianet Group highlighted as Zacks Bull and Bear of the Day Zacks
06:00AM  Chairmans Address to the Mesoblast 2017 Annual General Meeting GlobeNewswire
Nov-15-17 03:45PM  3 Stocks Under $10 That Plummeted Today Zacks -7.42%
Nov-14-17 05:35PM  Mesoblast Operational Highlights and Financial Results for the First Quarter Ended September 30, 2017 GlobeNewswire
Nov-13-17 04:30PM  Mesoblast to Host First Quarter Financial Results Webcast and Conference Call GlobeNewswire
Nov-10-17 09:49AM  Mesoblast Phase 2 Trial Results Show Early and Durable Effects of Single Mesenchymal Precursor Cell Infusion in Biologic Refractory Rheumatoid Arthritis Patients GlobeNewswire
Nov-09-17 06:00AM  Mesoblast Presents Corporate Update at 26TH Annual Credit Suisse Healthcare Conference GlobeNewswire
Nov-06-17 12:03PM  ETFs with exposure to Mesoblast Ltd. : November 6, 2017 Capital Cube
Oct-23-17 10:47AM  ETFs with exposure to Mesoblast Ltd. : October 23, 2017 Capital Cube
Oct-16-17 11:29PM  Should You Buy Mesoblast Limited (ASX:MSB)? Simply Wall St.
Oct-09-17 11:46AM  ETFs with exposure to Mesoblast Ltd. : October 9, 2017 Capital Cube
Oct-06-17 09:09AM  Mesoblast Ltd. :MESO-US: Earnings Analysis: Q4, 2017 By the Numbers : October 6, 2017 Capital Cube
Sep-28-17 06:00AM  Clinical Trial of Mesoblasts Cell Therapy in End-Stage Heart Failure Patients Completes Enrollment GlobeNewswire
Sep-25-17 07:27AM  Mesoblast Presents Corporate Updates at Global Healthcare Conferences GlobeNewswire
Sep-20-17 07:10AM  Earnings Review and Free Research Report: Mesoblast Reported Q4 and Full Year FY17 Results ACCESSWIRE
Sep-08-17 07:30AM  Featured Company News - Bio-Techne Acquires Trevigen in an All-cash Deal ACCESSWIRE
Sep-05-17 09:25PM  ETFs with exposure to Mesoblast Ltd. : September 6, 2017 Capital Cube
Sep-01-17 03:59PM  Mesoblast Ltd. :MESO-US: Earnings Analysis: 2017 By the Numbers : September 1, 2017 Capital Cube
Aug-29-17 06:42PM  Mesoblast Operational Highlights and Financial Results for the Fourth Quarter and for the Year Ended 30 June 2017 GlobeNewswire
Aug-23-17 06:00AM  Mesoblast Outlines Potential Pathway to Accelerated Market Entry for MPC-150-IM in Advanced Chronic Heart Failure GlobeNewswire
Aug-16-17 06:00AM  Positive Trial Results of Mesoblast Cell Therapy in Post-Traumatic Osteoarthritis Published In Arthritis Research & Therapy GlobeNewswire
Jun-22-17 06:00AM  Mesoblast Rheumatoid Arthritis Trial Results Presented at EULAR Annual European Congress of Rheumatology GlobeNewswire
Jun-05-17 02:31PM  ETFs with exposure to Mesoblast Ltd. : June 5, 2017 Capital Cube
Jun-02-17 10:22AM  Mesoblast Ltd. :MESO-US: Earnings Analysis: Q3, 2017 By the Numbers : June 2, 2017 Capital Cube
May-24-17 06:15PM  Mesoblast Operational Highlights and Financial Results for the Period Ended March 31, 2017 GlobeNewswire
May-09-17 04:48PM  ETFs with exposure to Mesoblast Ltd. : May 9, 2017 Capital Cube
Apr-10-17 06:00AM  Successful Interim Analysis of Efficacy Endpoint in Mesoblasts Phase 3 Trial for Chronic Heart Failure GlobeNewswire +6.70%
Apr-06-17 06:00AM  Mesoblast Receives A$3.7 Million From the Australian Government for Research and Development Activities GlobeNewswire
Apr-03-17 04:34PM  FDA Clears Heart Disease Trial at Harvard's Boston Childrens Hospital Using Mesoblast's Cell Therapy to Grow Heart Muscle in Children With Congenital Heart Disease GlobeNewswire
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, diabetic kidney diseases, and type 2 diabetic nephropathy. It operates in the United States, Australia, Singapore, the United Kingdom, and Switzerland. Mesoblast Limited has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; and JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in epidermolysis bullosa. The company was founded in 2004 and is headquartered in Melbourne, Australia.